• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Senti Biosciences Inc.

    4/30/25 4:28:45 PM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $SNTI alert in real time by email
    DEFA14A 1 a20250430defa14a.htm DEFA14A Document

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    SCHEDULE 14A INFORMATION
    Proxy Statement Pursuant to Section 14(a) of the
    Securities Exchange Act of 1934 (Amendment No.____)
    Filed by the Registrant x
    Filed by a Party other than the Registrant o
    Check the appropriate box:
    oPreliminary Proxy Statement
    oConfidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
    oDefinitive Proxy Statement
    xDefinitive Additional Materials
    oSoliciting Material under §240.14a-12
    SENTI BIOSCIENCES, INC.
    (Name of registrant as specified in its charter)
    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)
    Payment of Filing Fee (Check all boxes that apply):
    xNo fee required.
    oFee paid previously with preliminary materials;
    oFee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11






    additionalmaterial1.gif



    additionalmaterial2.gif

    Get the next $SNTI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SNTI

    DatePrice TargetRatingAnalyst
    10/7/2022$7.50Equal-Weight
    Morgan Stanley
    More analyst ratings

    $SNTI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Senti Biosciences Inc.

      SC 13D/A - Senti Biosciences, Inc. (0001854270) (Subject)

      12/4/24 7:08:03 PM ET
      $SNTI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Senti Biosciences Inc.

      SC 13G - Senti Biosciences, Inc. (0001854270) (Subject)

      2/14/23 12:38:17 PM ET
      $SNTI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Senti Biosciences Inc. (Amendment)

      SC 13G/A - Senti Biosciences, Inc. (0001854270) (Subject)

      2/14/23 11:52:00 AM ET
      $SNTI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SNTI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Celadon Partners Spv 24 converted options into 9,777,000 shares (SEC Form 4)

      4 - Senti Biosciences, Inc. (0001854270) (Issuer)

      3/14/25 11:52:40 AM ET
      $SNTI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 3 filed by new insider Celadon Partners Spv 24

      3 - Senti Biosciences, Inc. (0001854270) (Issuer)

      3/13/25 4:32:52 PM ET
      $SNTI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Large owner New Enterprise Associates 15, L.P. converted options into 3,333,000 shares (SEC Form 4)

      4 - Senti Biosciences, Inc. (0001854270) (Issuer)

      3/12/25 9:30:38 PM ET
      $SNTI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SNTI
    Leadership Updates

    Live Leadership Updates

    See more
    • Senti Bio Bolsters Scientific Advisory Board with Appointment of James B. Trager, Ph.D.

      Industry leader in the development and application of cellular therapies, including CAR NK products, for cancer Led development of multiple clinical candidates from conception through IND and early clinical development Vast experience in technology licensing, correlation from "bench to bedside" and back and execution of scientific strategy SOUTH SAN FRANCISCO, Calif., April 10, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio" or the "Company"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced the appointment of James B. Trager, Ph.D. to its Scientific Advisor

      4/10/25 8:45:00 AM ET
      $SNTI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SNTI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Senti Bio to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar

      SOUTH SAN FRANCISCO, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio" or the "Company"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that Timothy Lu, M.D., Ph.D. Co-Founder and Chief Executive Officer of Senti Bio, will present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar on Thursday, May 29, 2025 at 2:40 PM ET. Conference Details: Conference: LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar Date/Time: Thursday, May 29th at 2:40 PM ET Presenter: Timothy Lu, M.D., Ph.D. Co-Founder and Chi

      5/22/25 4:05:55 PM ET
      $SNTI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Senti Bio Receives Additional $1.0 Million Tranche from California Institute for Regenerative Medicines (CIRM) Grant for Advancing Clinical Development of SENTI-202

      SOUTH SAN FRANCISCO, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio" or the "Company"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today reported the receipt of an additional $1.0 million from the California Institute of Regenerative Medicine (CIRM) upon the achievement of clinical study enrollment milestones. As previously announced, the CIRM awarded an $8 million grant to Senti Bio to support the ongoing clinical development of SENTI-202, a potential first-in-class Logic Gated off-the-shelf chimeric antigen receptor natural killer (CAR-NK) investigationa

      5/22/25 8:30:00 AM ET
      $SNTI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Senti Bio Releases Mechanism of Action Video for First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, SENTI-202

      Access video here SOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio" or the "Company"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announces the release of its new animated video for its lead asset in development, SENTI-202. The video can be accessed here. SENTI-202 is the Company's First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy product candidate designed to selectively target and eliminate CD33 and/or FLT3-expressing hematologic malignancies, such as AML and myelodysplastic syndrome (

      5/8/25 8:35:00 AM ET
      $SNTI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SNTI
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Senti Biosciences Inc.

      SCHEDULE 13G/A - Senti Biosciences, Inc. (0001854270) (Subject)

      5/15/25 4:43:33 PM ET
      $SNTI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Senti Biosciences Inc.

      SCHEDULE 13G/A - Senti Biosciences, Inc. (0001854270) (Subject)

      5/15/25 4:41:42 PM ET
      $SNTI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Senti Biosciences Inc.

      SCHEDULE 13G/A - Senti Biosciences, Inc. (0001854270) (Subject)

      5/15/25 4:36:10 PM ET
      $SNTI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SNTI
    Financials

    Live finance-specific insights

    See more
    • Senti Bio to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar

      SOUTH SAN FRANCISCO, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio" or the "Company"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that Timothy Lu, M.D., Ph.D. Co-Founder and Chief Executive Officer of Senti Bio, will present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar on Thursday, May 29, 2025 at 2:40 PM ET. Conference Details: Conference: LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar Date/Time: Thursday, May 29th at 2:40 PM ET Presenter: Timothy Lu, M.D., Ph.D. Co-Founder and Chi

      5/22/25 4:05:55 PM ET
      $SNTI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Senti Bio Receives Additional $1.0 Million Tranche from California Institute for Regenerative Medicines (CIRM) Grant for Advancing Clinical Development of SENTI-202

      SOUTH SAN FRANCISCO, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio" or the "Company"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today reported the receipt of an additional $1.0 million from the California Institute of Regenerative Medicine (CIRM) upon the achievement of clinical study enrollment milestones. As previously announced, the CIRM awarded an $8 million grant to Senti Bio to support the ongoing clinical development of SENTI-202, a potential first-in-class Logic Gated off-the-shelf chimeric antigen receptor natural killer (CAR-NK) investigationa

      5/22/25 8:30:00 AM ET
      $SNTI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Senti Bio Releases Mechanism of Action Video for First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, SENTI-202

      Access video here SOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio" or the "Company"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announces the release of its new animated video for its lead asset in development, SENTI-202. The video can be accessed here. SENTI-202 is the Company's First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy product candidate designed to selectively target and eliminate CD33 and/or FLT3-expressing hematologic malignancies, such as AML and myelodysplastic syndrome (

      5/8/25 8:35:00 AM ET
      $SNTI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SNTI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Morgan Stanley initiated coverage on Senti Bio with a new price target

      Morgan Stanley initiated coverage of Senti Bio with a rating of Equal-Weight and set a new price target of $7.50

      10/7/22 7:14:34 AM ET
      $SNTI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care